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Abstract 
AIM: Evaluation the effect of intralesional corticosteroid injection on keloid, at the National Hospital of 
Dermatology and Venereology from 1/2009 to 12/2009.  
METHODS: A group of 65 patients with keloid were randomly assigned into three groups. In the studied group, 33 
patients were intralesionally injected 7.5 mg/1 cm
2
 of TCA. In the control group, TAC 32 patients were 
intralesionally injected 15 mg/1 cm
2
 of TCA. The result was evaluated basing on the criteria of Henderson (1998) 
and El-Tonsy (1996).  
RESULTS: In comparison between 2 groups, good to excellent improvement in the studied group was statistically 
higher than the control group (90.7% versus 68.7%; p < 0.05). After each injection, the thickness of the scar was 
reduced 1.24 ± 0.53 mm in the studied group and 0.81 ± 0.39 mm in the control group. The disappearance of pain 
and itching after treatment were 86.6% and 95.5% in the studied group and 78.1% and 80% in the control group 
(p > 0.05). Ulceration, acne and troublesome with menstrual cycles were sometimes were noted more frequently 
in the control group than in the studied group.  
CONCLUSION: Intralesional triamcinolone acetonide injection had a good result, and 7.5 mg/1 cm
2
 scar is the 
best dose for treatment of keloid. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Keloid is a benign condition of the skin 
caused by excessive deposition of fibrous cells and 
collagen fibres in the body. It occurs at all ages, both 
sexes and all races. Blacks have the highest rates of 
keloid, followed by yellow and white. 
In recent years, thanks to advances in 
molecular biology, the pathogenesis of keloids and 
hypertrophic scars has been clarified. Particularly, 
fibroblast growth factor (FGF) and transforming 
growth factor-beta (TGF-) play a pivotal role in the 
development of scars [1], [2]. 
Although there are many different treatments 
of keloids nowadays, such as surgical excision, laser, 
cryotherapy, radiotherapy, silicone gel, corticosteroid 
injection. PDT, however, each method has its 
advantages and disadvantages, and the results also 
vary depending on each study [3]. Injections of 
corticosteroids have also been introduced in Vietnam. 
However, up to now, there have been no studies 
about the doses, effects and the unwanted effects of 
keloids treatment with Triamcinolone injections.  
We aimed evaluation the effect of intralesional 
corticosteroid injection on keloid, at the National 
Hospital of Dermatology and Venereology from 
1/2009 to 12/2009. 
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Methods 
 
An open clinical trial (self-comparison before 
and after treatment) on 65 patients with keloids was 
conducted at the Department of Laser and Surgical of 
Dermatology Central Hospital of Vietnam from 
January 2009 to December 2009. 
Included 65 patients were randomised into 2 
equal groups: a studied group of 33 patients received 
TAC injection with a dose of 7.5 mg/1 cm
2
 scars 
acreage and control group of 32 patients received 
TAC injection with a dose of 15 mg/1 cm
2
 scars 
acreage. 
Patients are given repeated doses every 4 
weeks, and totally does not exceed 60 mg/each time. 
Average treatment times 4-6 times. 
Evaluation of treatment outcome: Based on 
clinical evaluation criteria of Henderson (1998) and El-
Tonsy (1996) [4]. 
- Flat scars: 1 point. 
- Soft scars (equivalent to surrounding 
normal skin): 1 point. 
- Bright colour scars (equivalent to 
surrounding normal skin colour): 1 point. 
- No functional symptoms (itching, 
pain): 1 point. 
- No recurrence: 3 points. 
- Recurrence on a small acreage of 
scar: 1 point. 
- Recurrence on a large scale: 0 points. 
- No side effects: 3 points. 
- Side effects do not stop treatment: 1 
point. 
- Side effects stop treatment: 0 points. 
- The maximum score is 10 points; 
minimum is 0 points. 
Evaluate treatment results in three levels: 
Good at 9-10 points, Quite good at 7-8 points and 
Poor when below 7 points. 
- Evaluation of side effects and 
complications: 
 Local: 
An ulcer caused by treatment, ulcer healing 
time. 
I am surrounding area vasodilation. 
Atrophic skin in the surrounding area. 
 Whole body: 
Acne. 
Menstrual disorders in women. 
Hypertension. 
Chronic gastritis. 
 Other undesirable effects (if any). 
- Treatment stop: 
 When results are good: scars are 
stable, flat, soft and free of local functional symptoms, 
and the thickness of scars after the ultrasound is 
equivalent to the surrounding normal skin. The 
injection can be stopped at any time ≤ 6 times when 
clinical show success. 
 When the patient does not respond to 
treatment: the patient follows the right course of 
treatment from 4 to 6 times, but scars continue to 
develop, local functional symptoms do not decrease. 
 When the patient has some side 
effects or newly infected diseases such as 
gastrointestinal ulcer, gastrointestinal bleeding, 
systemic tuberculosis infection, severe menstrual 
disorders, Cushing's syndrome. 
 
 
Results 
 
General characteristics of the included 
objects  
At the initiation time of treatment, there was 
no difference in age, gender, number, area, thickness 
and progression of scar between the two groups.  
 
Treatment results 
The good and quite good results in the 
studied group (66.7%, 24.2%) are higher than in 
control group (53.1%, 16.5%) with p < 0.05 as shown 
in see Table 1.  
Table 1: Evaluation of treatment results 
After scars treatment 
evaluation score 
Studied group Control group 
n % n % 
Good (9 – 10 pts) 8 24.2 5 15.6 
Quite good (7 – 8 pts) 22 66.7 17 53.1 
Poor (< 7 pts) 3 9.1 10 31.3 
p < 0.05    
 
Unwanted effects 
Side effects may include ulcers, acne, 
menstrual disorders and frequency of occurrence in 
the control group is higher than the studied group as 
shown in Table 2. 
Table 2: Side effects in two study groups (n = 65) 
Side effects 
Studied group Control group Summary 
 n % n % n % 
Local 
Ulcers 1 3.0 6 18.6 7 10.8 
Vasodilatation 
and atrophic 
skin 
0 0 0 0 0 0 
Whole body 
Acnes 0 0 2 6.4 2 3.1 
Menstrual 
disorders 
1/18 5.6 4/16 25 5/34 14.7 
Hypertension 1 3.0 1 3.1 2 3.1 
Gastritis 0 0 0 0 0 0 
Other  0 0 0 0 0 0 
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Discussion 
 
Keloids are benign, but severely affect the 
quality of life. Especially with continuous development 
feature, keloids can cause distortion, limiting joint 
mobility. Until now, there are no measures to cure 
keloids completely. Study shows that corticosteroid 
intralesional injections in both groups yield good 
results. In studied group, the number of patients 
receiving TAC injections at doses of 7.5 mg/square 
cm achieved quite good and good results (90.7%) is 
higher than control group who received TAC injection 
at doses of 15 mg/square cm (68.7%), this difference 
was statistically significant at p < 0.05. Triamcinolone 
inhibits the growth of fibrous cells and reduces 
collagen deposition in lesions [6], [7]. 
Tingling and pain at the lesions sites are very 
common functional symptoms and also cause the 
patient to come to the clinic. These symptoms heavily 
affect the quality of life of patients [8]. Our results 
show that 82.3% of the cases had no itch on the 
lesions after treatment in both groups; over 75.9% had 
no pain on the lesions in both groups. 
The case of itching and pain can be due to 
the nerve extremities are no longer confined due to 
the decrease in density of fibrous cells and collagen 
fibres after corticoid injection. Corticosteroids also 
have an anti-inflammatory effect that reduces vascular 
permeability, inhibits the production of chemical 
intermediates that reduce inflammation, itch and pain. 
Accurately measurement of the thickness of the 
scars is a very difficult matter. In the past, most studies 
assessed the thickness by measuring the elevation of the 
scar compared to the surrounding normal skin [2], [4]. 
This method is simple but inaccurate because most of the 
thickness of the scar is in the dermis. To determine the 
thickness of the scar we use Philip HD II ultrasound 
machine with high-frequency probes. This is a highly 
reliable measure, first used to accurately measure the 
thickness of the scar with a deviation of 0.01 mm. We are 
determining the thickness of scars before treatment and 
the average level of slack after each injection helps us to 
plan treatment. 
In both groups, the mean scar thickness 
before treated was 5.50 mm. The mean scar 
thickness reduction after each injection in the studied 
group was 0.81 ± 0.39 mm, in the control group was 
1.24 ± 0.53 mm. After treatment, the scar thickness 
was 2-3 times lower than before treatment (p < 0.05), 
the thickness of the scar corresponded to normal skin 
(1.9 mm). 
Evaluation of skin flatness after treatment 
showed that in the studied group, 78.8% of patients 
had flattened scars, while in the control group, this 
rate was 65.6%. To achieve flatness compared to the 
surrounding skin, the studied group had to inject 3.5 
times on average, while the control group had to inject 
3 times on average. The results of Manuskiatti's 
research are similar to our results. After 2 injections of 
TAC (8 weeks), the thickness of the scar returned to 
normal compared with the surrounding skin [5]. None 
of the 65 patients in our study had flattened scars 
after one injection. 
The softness of the skin is also an important 
criterion for evaluating treatment success. After 
treatment, the softness of scar in both groups 
improved significantly. However, there was no 
significant difference in comparison between the two 
groups. 
There were 7 patients with scars ulcer after 
injected, one in studied group (3.0%) and 6 in the 
control group (18.6%). The cause of ulcer may be due 
to high dosage. This explains our results in the control 
group, patients treated with high doses (30 mg/1 ml) 
twice as often as studied group (15 mg/1 ml) should 
have more ulcer patients. The study of A. Darougheh 
in 20 keloids patients treated with triamcinolone of 20 
mg/1ml injections showed no cases of the ulcer. 
However, our results in the studied group, one patient 
treated with lower doses (15 mg/1 ml) also have an 
ulcer after injection. This may be due to too-shallow 
injection techniques, which are also responsible for 
ulcers. Most cases of scar ulcers occur after 3 to 4 
treatment times. Therefore, after the second injection 
the thickness of the scar should be noted, and 
especially injections should not be too shallow to 
avoid ulceration in this injection. 
In the control group, there were 2 cases 
(6.25%) of acne reappearing in a total of 6 patients 
with a history of stable, treated acne. No cases of 
acne appear in patients with no history of acne before 
treatment. In the studied group, we did not find any 
cases of post-treatment acne (9 patients had a history 
of acne before treatment). Thus, when using high-
dose topical corticosteroid therapy for keloids in 
patients with a history of acne, there is a risk of 
recurrence of acne. Therefore, for patients with post-
acne keloid, it is best not to use corticosteroids 
therapy. These patients should take other therapies 
such as cold surgery or colour laser. 
There were 5/34 female patients in both 
groups with menstrual disorders, with only 1/18 
patient in the studied group and 4/16 patients in the 
control group. These patients had bleeding days 
increased 2-3 days, in contrast to the cycle is 
shortened by 5-7 days. This menstrual disorder 
usually occurs after 2 to 4 treatments but not severe, 
and after a short rest period from treatment, the 
menstrual period returns to normal. 
There are two cases of hypertension during 
treatment, in which one patient in the control group 
suffered hypertension and ulceration at the lesion 
after treatment 4 times, so we stopped this patient 
treatment. A study by Daruogheh A. found that 37% of 
patients exhibited atrophy skin and vasodilatation [2]. 
However, we do not see any cases of skin atrophy 
around scars, vasodilatation or drug-induced gastritis. 
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This may be due to the fact that most of our patients 
have a low number of lesions, scar acreage is small, 
so the amount of drug used is not much. Therefore, in 
our experience, to minimise the side effects of the 
drug, patients should not be injected more than 60 mg 
each injection. 
In conclusion, triamcinolone injections were 
effective in treating keloids: Studied group had a 
higher proportion of patients with quite good and good 
treatment results (90.7%) than in control group quite 
good and good results (68.7%) with p < 0.05. The rate 
of patients ceased itching, and pain post-treatment in 
the studied group was 86.6%, and 95.5%; Similar in 
control group is 78.1% and 80%. Although the 
average reduction in scars thickness after each 
injection in the control group (1.24 ± 0.53 mm) was 
significantly higher than in the studied group (10.81 ± 
0.39 mm) (p < 0.05), however, some side effects such 
as ulceration at the lesions, acne, menstrual disorder, 
are less common in the studied group (7.5 mg/1 cm
2
). 
Therefore, the treatment of keloids with Triamcinolone 
injection dose of 7.5 mg/1cm
2
 showed best results. 
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